Oral Biolife (OBL), a biotechnology firm focused on innovative dental treatments for both humans and pets, has announced significant advancements in its research on periodontal disease. The company revealed promising data from studies conducted on Beagle dogs, which indicates that its leading product, Ambrilux Dental Gel, effectively promotes bone regeneration in cases of induced periodontal disease.
In the study, radiographs were taken at the baseline, 28 days after the first application of the gel, and again 29 days after a second application. Results showed that 100% of the treated dogs exhibited increased bone regeneration at both intervals.
In contrast, only 33% of control dogs demonstrated any detectable bone growth. This finding suggests that Ambrilux Dental Gel may have strong potential for translating into human treatments for periodontal disease.
Importantly, no adverse events or safety issues were reported during the study. An adverse event is defined as any unexpected and unfavorable observation in treated animals following the use of an investigational product.
Bill Breitenbach, CEO of Oral Biolife, emphasized the significance of these results, stating, “This proof-of-concept marks a major milestone in our journey. It reinforces our confidence that Ambrilux Dental Gel has the potential to revolutionize how dental care is provided, offering a less invasive and more accessible option for patients.”
Periodontal disease affects nearly 20% of the global population and about 47% of adults in the U.S., leading to an estimated loss of $54 billion annually in productivity. These statistics highlight a pressing need for effective non-invasive treatment options. Oral Biolife’s findings represent a significant step toward addressing this unmet need in dental health.
Stella Vnook, President of Oral Biolife, reiterated the company’s mission to provide accessible non-invasive dental care. “We are pleased with these promising results and are excited to continue our research to further establish the safety and efficacy of the Ambrilux Dental Gel,” she stated.
The breakthrough data from Oral Biolife positions Ambrilux Dental Gel as a potential game-changer in the field of periodontal treatment, paving the way for future studies and applications in both veterinary and human medicine.
Related topics: